Pharmacologic Modification of Acute Cerebral Ischemia

Stroke: Pathophysiology, Diagnosis, and Management

Volumn , Issue , 2004, Pages 1025-1058

  Labiche, Lise A ^a   Grotta, James C ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33645442981     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-44-306600-0/50061-4     Document Type: Chapter

References (310)

1. Hossmann K Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994, 36:557.
2. Ginsberg MD Neuroprotection in brain ischemia: An update (parts I and II). Neuroscientist 1995, 1:95. 164.
3. DeGraba TJ, Ostrow PT, Strong RA, et al. The temporal relation of calcium-calmodulin binding and neuronal damage after global ischemia. Stroke 1992, 23:876.
4. Bredesen DE Neural apoptosis. Ann Neurol 1995, 38:839.
5. Sharp FR, Lu A, Tang Y, Milhorn DE Multiple molecular penumbras after focal cerebral ischemia. J Cereb Blood Flow Metab 2000, 20:1011.
6. Pulsinelli WA, Brierley JB A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke 1979, 10:267.
7. Pulsinelli WA, Brierley JB, Plum F Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann Neurol 1982, 11:491.
8. Volpe BT, Pulsinelli WA, Tribuna J, Davis HP Behavioural performance of rats following transient forebrain ischemia. Stroke 1984, 15:558.
9. Chen ST, Hsu CY, Hogan EL, et al. A model of focal ischemic stroke in rats: Reproducible extensive cortical infarction. Stroke 1986, 17:738.
10. Brint S, Jacewicz M, Kiessling M, et al. Focal brain ischemia in rat: Method for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral and ipsilateral common carotid arteries. J Cereb Blood Flow Metab 1988, 8:474.
11. Buchan A, Xue D, Slivka A A new model of temporary focal neocortical ischemia in the rat. Stroke 1992, 23:273.
12. Zhang RL, Zhang ZG, Chopp M Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat. Neurology 1999, 52:273.
13. Yang G, Betz L Reperfusion-induced injury to the blood-brain barrier after middle cerebral artery occlusion in rats. Stroke 1994, 25:1658.
14. Aronowski J, Strong R, Grotta J Reperfusion injury: Demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. J Cereb Blood Flow Metab 1997, 17:1048.
15. Uematsu D, Araki N, Greenberg J, et al. Combined therapy with MK-801 and nimodipine for protection of ischemic brain damage. Neurology 1991, 41:88.
16. Zivin J, Mazzarella V Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke. Arch Neurol 1991, 48:1235.
17. Bowes M, Rothlein R, Fagan S, Zivin J Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology 1995, 45:815.
18. Grotta JC The current status of neuronal protective therapy: Why have all neuronal protective drugs worked in animals but none so far in stroke patients?. Cerebrovasc Dis 1994, 4:115.
19. Fisher M, Ratan R New perspectives on developing acute stroke therapy. Ann Neurol 2003, 53:10.
20. Jones TH, Morawetz RB, Crowell RM, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 1981, 54:773.
21. Kaplan B, Brint S, Tanabe J, et al. Temporal thresholds for neocortical infarction in rats subjected to reversible focal cerebral ischemia. Stroke 1991, 22:1032.
22. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002, 346:557.
23. The Hypothermia After Cardiac Arrest Study Group Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002, 346:549.
24. Colbourne F, Li H, Buchan AM Indefatigable CA1 sector neuroprotection with mild hypothermia induced 6 hours after severe forebrain ischemia in rats. J Cereb Blood Flow Metab 1999, 19:742.
25. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999, 30:2752.
26. Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001, 32:1598.
27. Adams HP, Davis PH, Leira EC, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke. Neurology 1999, 53:126.
28. Woo D, Broderick J, Kothari R, et al. Does the National Institutes of Health Stroke Scale favor left hemisphere strokes?. Stroke 1999, 30:2355.
29. Heiss WD, Graf R, Lottgen J, et al. Repeat positron emission tomographic studies in transient middle cerebral artery occlusion in cats: Residual perfusion and efficacy of postischemic reperfusion. J Cereb Blood Flow Metab 1997, 17:388.
30. Baron JC Mapping the ischemic penumbra with PET: Implications for acute stroke treatment. Cerebrovasc Dis 1999, 9:193.
31. Marchal G, Beaudoin V, Rioux P, et al. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke. Stroke 1996, 27:597.
32. Neumann-Haeflin T, Moseley ME, Albers GW New magnetic resonance imaging methods for cerebrovascular disease: Emerging clinical applications. Ann Neurol 2000, 31:559.
33. Schellinger PD, Fieback JB, Jansen O, et al. Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Ann Neurol 2001, 49:460.
34. Schlaug G, Benfield A, Baird AE, et al. The ischemic penumbra: Operationally defined by diffusion perfusion MRI. Neurology 1999, 53:1528.
35. Li F, Silva MD, Liu KF, et al. Secondary decline in apparent diffusion coefficient and neurological outcome after a short period of focal brain ischemia in rats. Ann Neurol 2000, 48:236.
36. Kidwell CS, Saver JL, Mattiello J, et al. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol 2000, 47:462.
37. Warach S, Pettigrew LC, Dashe JF, et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol 2000, 48:713.
38. Tissue plasminogen activator for acute ischemic stroke The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995, 333:1581.
39. Lees KR, Asplund K, Carolei A, et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: A randomized controlled trial. The GAIN International Investigators. Lancet 2000, 355:1949.
40. Muir KW Magnesium for neuroprotection in ischaemic stroke: Rationale for use and evidence of effectiveness. CNS Drugs 2001, 15:921.
41. Davalos A, Castillo J, Alvarez-Sabin J, et al. Oral citicoline in acute ischemic stroke: An individual patient data pooling analysis of clinical trials. Stroke 2002, 33:2850.
42. Grotta J Combination Therapy Stroke Trial: Recombinant tissue-type plasminogen activator with/without lubeluzole. Cerebrovasc Dis 2001, 12:258.
43. Saver JL, Kidwell CS, Leary M, et al: The Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial: A study of prehospital neuroprotective therapy. Abstract presented at the Ongoing Clinical Trials Session, 26th International Stroke Conference, February 13-15, 2001, Fort Lauderdale, FL.
44. Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measure by computed tomography The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Stroke 2000, 31:2912.
45. Hantson L Neurologic scales in the assessment of stroke. Ischemic Stroke: Recent Advances in Understanding and Therapy 1995, International Business Communications, Southbourough, MA. J. Grotta, L. Miller, A.M. Buchan (Eds.).
46. Duncan PW, Lai SM, Bode RK, et al. Stroke impact scale-16. Neurology 2003, 60:291.
47. Tilley BC, Marler J, Geller N, et al. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA stroke trial. Stroke 1996, 27:2136.
48. Bean BP Nitrendipine block of cardiac calcium channels: High-affinity binding to the inactivated state. Proc Natl Acad Sci U S A 1984, 81:6388.
49. Horn J, de Haan RJ, Verneulen M, et al. Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. Stroke 2001, 32:2433.
50. Grotta JC Clinical aspects of the use of calcium antagonists in cerebrovascular disease. Clin Neuropharmacol 1991, 14:373.
51. Horn J, Limburg M Calcium antagonists for ischemic stroke: A systematic review. Stroke 2001, 32:570.
52. Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients: Results of a multicenter double-blind placebo-controlled trial. J Neurosurg 1988, 68:505.
53. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British Aneurysm Nimodipine Trial. BMJ 1989, 298:636.
54. Ohman J, Servo A, Heiskanen O Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg 1991, 74:8.
55. Barker FG, Ogilvy CS Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: A meta-analysis. J Neurosurg 1996, 84:405.
56. Feigin VL, Rinkel GJ, Algra A, et al: Calcium antagonists for aneurismal subarachnoid haemorrhage. Cochrane Database Syst Rev CD000277, 2000.
57. Roine RO, Kaste M, Kinnunen A, et al. Nimodipine after resuscitation from out-of-hospital ventricular fibrillation: A placebo-controlled, double-blind, randomized trial. JAMA 1990, 264:3171.
58. Gelmers HJ The effects of nimodipine on the clinical course of patients with acute ischemic stroke. Acta Neurol Scand 1984, 69:232.
59. Gelmers HJ, Gorter K, de Weerdt CJ, Wiezer HJ A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med 1988, 318:203.
60. Paci A, Ottaviano P, Trenta A, et al. Nimodipine in acute ischemic stroke: A double-blind controlled study. Acta Neurol Scand 1989, 80:282.
61. Gelmers HJ, Hennerici M Effect of nimodipine on acute ischemic stroke: Pooled results from 5 randomized trials. Stroke 1990, 21(Suppl):IV81.
62. Nag D, Garg RK, Varma M A randomized double-blind controlled study of nimodipine in acute cerebral ischemic stroke. Indian J Physiol Pharmacol 1998, 42:555.
63. Clinical trial of nimodipine in acute ischemic stroke The American Nimodipine Study Group. Stroke 1992, 23:3.
64. Wahlgren N, MacMahon D, De Keyser J, et al. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischemic stroke. The INWEST Study Group. Cerebrovasc Dis 1994, 4:204.
65. Kaste M, Fogelholm R, Erila T, et al. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 1994, 25:1348.
66. Ahmed N, Nasman P, Wahlgren NG Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke 2000, 31:1250.
67. Mohr J, Orgogozo J, Harrison M, et al. Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 1994, 4:197.
68. Horn J, de Haan RJ, Verneulen M, Limburg M Very Early Nimodipine Use in Stroke (VENUS): A randomized, double-blind, placebo-controlled trial. Stroke 2001, 32:461.
69. Haley C, Kassel N, Torner J, et al. A randomized controlled trial of high dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage-a report of the Cooperative Aneurysm Study. J Neurosurg 1993, 78:537.
70. Rosenbaum D, Zabramski J, Frey J, et al. Early treatment of ischemic stroke with a calcium antagonist. Stroke 1991, 22:437.
71. Kobayashi T, Mori Y Ca channel antagonists and neuroprotection from cerebral ischemia. Eur J Pharmacol 1998, 363:1.
72. Koh JY, Cotman CW Programmed cell death: Its possible contribution to neurotoxicity mediated by calcium channel antagonists. Brain Res 1992, 587:233.
73. Buchan AM, Gertler SZ, Li H, et al. A selective N-type Ca channel blocker prevents CA1 injury 24h following severe forebrain ischemia and reduces infarction following focal ischemia. J Cereb Blood Flow Metab 1994, 14:903.
74. Grotta JC, Picone CM, Ostrow PT, et al. CGS-19755, a competitive NMDA receptor antagonist, reduces calcium-calmodulin binding and improves outcome after global cerebral ischemia. Ann Neurol 1990, 27:612.
75. Simon R, Shiraishi K N-methyl- d-aspartate antagonist reduces stroke size and regional glucose metabolism. Ann Neurol 1990, 27:606.
76. Simmonds J, Sailer T, Moyer J The effects of CGS-19755 in rat focal cerebral ischemia produced by tandem ipsilateral common carotid artery and middle cerebral artery occlusion [abstract]. Soc Neurosci Abstr 1993, 19:1647.
77. Grotta J, Clark W, Coull B, et al. Safety and tolerability of the glutamate antagonist CGS 1975 (selfotel) in patients with acute ischemic stroke: Results of a phase IIa randomized trial. Stroke 1995, 26:602.
78. Davis SM, Lees KR, Albers GW, et al. selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist. The ASSIST Investigators. Stroke 2000, 31:347.
79. Steinberg GK, Perez-Pinzon MA, Maier CM, et al: CGS-19755: Correlation of in vitro neuroprotection, protection against experimental ischemia and CSF levels in cerebrovascular surgery patients [abstract]. In Proceedings of the 5th International Symposium on Pharmacology of Cerebral Ischemia, July 20-22, 1994, Marburg, Germany.
80. Albers GW, Atkinson RP, Kelley RE, et al. Safety, tolerability, and pharmacokinetics of the N-methyl-B aspartate antagonist dextrorphan in patients with acute stroke. Stroke 1995, 26:254.
81. Minematsu K, Fisher M, Li L, et al. Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion-weighted MRI. Neurology 1993, 43:397.
82. Dyker AG, Edwards KR, Fayad PB, et al. Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke. Stroke 1999, 30:2038.
83. Albers GW, Goldstein LB, Hall D, et al. Aptiganel hydrochloride in acute ischemic stroke: A randomized controlled trial. Aptiganel Acute Stroke Investigators. JAMA 2001, 21:2673.
84. Diener HC, AlKhedr A, Busse O, et al. Treatment of acute ischaemic stroke with the low affinity, use-dependent NMDA antagonist AR-R15896AR: A safety and tolerability study. J Neurol 2002, 249:561.
85. Muir KW Magnesium in stroke treatment. Postgrad Med J 2002, 78:641.
86. Muir KW, Lees DR A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke 1995, 126:1183.
87. Weglicki WB, Phillips TM Pathobiology of magnesium deficiency: A cytokine/neurogenic inflammation hypothesis. Am J Physiol 1992, 263:R734.
88. Yang Y, Li Q, Ahmad F, Shuaib A Survival and histological evaluation of therapeutic window of post-ischemia treatment with magnesium sulfate in embolic stroke model of rat. Neurosci Lett 2000, 285:119.
89. Altura BT, Memon ZI, Zhang A, et al. Low levels of serum ionized magnesium are found in patients early after stroke which result in rapid elevation in cytosolic free calcium and spasm in cerebral vascular muscle cells. Neurosci Lett 1997, 230:37.
90. Lampl Y, Geva D, Gilad R, et al. Cerebrospinal fluid magnesium level as a prognostic factor in ischaemic stroke. J Neurol 1998, 245:584.
91. Muir KW, Lees KR Dose optimization of intravenous magnesium sulfate after acute stroke. Stroke 1998, 29:918.
92. Izumi Y, Roussl S, Pinard E, Seylaz J Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rates. J Cereb Blood Flow Metab 1991, 11:1025.
93. Saver JL, Kidwell CS, Hamilton S, et al: The Field Administration of Stroke Therapy-Magnesium (FAST-MAG) Phase 3 Trial. Abstract presented at the Ongoing Clinical Trials Session, 27th International Stroke Conference, February 7-9, 2002, San Antonio, Texas.
94. Intravenous Magnesium Efficacy in Stroke Stroke Center Clinical Trials Directory. Available at Updated 07/30/2002 . http://www.mtsinai.org/pulmonary/books/house/legal.html.
95. Olney JW, Labruyere J, Price MT Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989, 244:1360.
96. Horvath ZC, Czopf J, Buzsaki G MK-801-induced neuronal damage in rats. Brain Res 1997, 753:181.
97. Farber NB, Kim SH, Dikranian K, et al. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 2002, 7:32.
98. Kim SH, Price MT, Olney JW, Farber NB Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and alpha2-adrenergic agonists. Mol Psychiatry 1999, 4:344.
99. Olney JW, Wozniak DF, Jevtovic-Todorovic V, et al. Drug-induced apoptotic neurodegeneration in the developing brain. Brain Pathol 2002, 12:488.
100. Lees KR Cerestat and other NMDA antagonists in ischemic stroie. Neurology 1997, 49(Suppl 4):S66.
101. Bordi F, Pietra C, Ziviani L, Reggiani A The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAO model of focal ischemia in the rat. Exp Neurol 1997, 145:425.
102. Dyker AG, Lees KR Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl- d-aspartate receptor) in patients with acute stroke. Stroke 1999, 30:986.
103. Phase II studies of the glycine antagonist GV150526 in acute stroke The North American experience. The North American Glycine Antagonist in Neuroprotection (GAIN) Investigators. Stroke 2000, 31:358.
104. Lees KR, Lavelle JF, Cunha L, et al. Glycine antagonist (GV150526) in acute stroke: A multicentre, double-blind placebo-controlled phase II trial. The GAIN Phase II European Study Group. Cerebrovasc Dis 2001, 11:20.
105. Sacco RL, DeRosa JT, Haley C, et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: A randomized controlled trial. The GAIN Americas Investigators. JAMA 2001, 285:1719.
106. Akins PT, Atkinson RP Glutamate AMPA receptor antagonist treatment for ischaemic stroke. Curr Med Res Opin 2002, 18(Suppl 2):S9.
107. Kawasaki-Yatsugi S, Ichiki C, Yatsugi S, et al. Neuroprotective effects of an AMPA receptor antagonist YM872 in a rat transient middle cerebral artery occlusion model. Neuropharmacology 2000, 39:211.
108. Van Hoogdalem E, de Vos R, Hefting NR, Napoliello MJ Clinical experience with YM872, a novel AMPA receptor antagonist for acute ischemic stroke [abstract]. Stroke 1999, 30:264.
109. Suzuki M, Sasamata M, Miyata K Neuroprotective effects of YM872.coadministered with t-PA in a rat embolic stroke model. Brain Res 2003, 959:169.
110. Elting JW, Sulter GA, Kaste M, et al. AMPA antagonist ZK200775 in patients with acute ischemic stroke: Possible glial cell toxicity detected by monitoring of S-100B serum levels. Stroke 2002, 33:2813.
111. Smith SE, Meldrum BS Cerebroprotective effect of lamotrigine after focal ischemia in rats. Stroke 1995, 26:117.
112. Traystman RJ, Klaus JA, DeVries AC, et al. Anticonvulsant lamotrigine administered on reperfusion fails to improve experimental stroke outcomes. Stroke 2001, 32:783.
113. Leach MJ, Swan JH, Eisenthal D, et al. BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke 1993, 24:1063.
114. Kawaguchi K, Graham SH Neuroprotective effects of the glutamate release inhibitor 619C89 in temporary middle cerebral artery occlusion. Brain Res 1991, 749:131.
115. Muir KW, Holzapfel L, Lees KR Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke. Cerebrovasc Dis 2000, 10:431.
116. Sipatrigine in Stroke (SIS). Stroke Center Clinical Trials Directory. Available at . http://www.mtsinai.org/pulmonary/books/house/legal.html.
117. Fosphenytoin Phase 3 Stroke Center Clinical Trials Directory. Available at Updated 8/3/2000 . http://www.mtsinai.org/pulmonary/books/house/legal.html.
118. Gribkoff VK, Starrett JE, Dworetzky SI The pharmacology and molecular biology of large-conductance calcium-activated (BK) potassium channels. Adv Pharmacol 1997, 37:319.
119. Bozik M, Hommel M, Grotta J, et al. Efficacy and safety of Maxi-Post TM in patients with acute stroke [abstract]. J Neurol Sci 2001, 187:s252.
120. Squire I, Lees K, Pryse-Phillips W, et al. The effects of lifarizine in acute cerebral infarction: A pilot safety study. The Lifarizine Study Group. Cerebrovasc Dis 1996, 6:156.
121. DeRyck M, Keersmaekers R, Clincke G, et al. Lubeluzole, a novel benzothiazole, protects neurologic function after cerebral thrombotic stroke in rats: An apparent stereospecific effect [abstract]. Soc Neurosci Abstr 1994, 20:185.
122. Aronowski J, Strong R, Grotta JC Treatment of experimental focal ischemia in rats with lubeluzole. Neuropharmacology 1996, 35:689.
123. DeRyck M, Verhoye M, Van der Linden AM Diffusion-weighted MRI of infarct growth in a rat photochemical stroke model: Effect of lubeluzole. Neuropharmacology 2000, 39:691.
124. Hernandez-Guijo JM, Gandia L, de Pascual R, Garcia AG Differential effects of the neuroprotectant lubeluzole on bovine and mouse chromaffin cell calcium channel subtypes. Br J Pharmacol 1997, 122:275.
125. Scheller DKA, DeRyck M, Kolb J, et al. Lubeluzole blocks increases in extracellular glutamate and taurine in the peri-infarct zone in rats. Eur J Pharmacol 1997, 338:243.
126. Lesage AS, Peeters L, Leysen JE Lubeluzole, a novel long-term neuroprotectant, inhibits the glutamate-activated nitric oxide synthase pathway. J Pharmacol Exp Ther 1996, 279:759.
127. Diener H, Hacke W, Hennerici M, et al. Lubeluzole in acute ischemic stroke: A double blind placebo controlled phase II trial. The Lubeluzole International Study Group. Stroke 1996, 27:76.
128. DeRyck M, Keersmackers R, Duytschaever H, et al. Lubeluzole protects sensorimotor function and reduces infarct size in a photochemical stroke model. J Pharmacol Exp Ther 1996, 35:748.
129. Diener HC Multinational randomized controlled trial of lubeluzole in acute ischaemic stroke: European and Australian Lubeluzole Ischaemic Stroke Study Group. Cerebrovasc Dis 1998, 8:172.
130. Grotta J Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group. Stroke 1997, 28:2338.
131. Diener HC, Cortens M, Ford G, et al. Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. The LUB-INT-13 Investigators. Stroke 2000, 31:2543.
132. Gandolfo C, Sandercock P, Conti M: Lubeluzole for acute ischaemic stroke. Cochrane Database Syst Rev CD001924, 2002.
133. Davies MF, Deisz RA, Prince DA, Peroutka SJ Two distinct effects of 5-hydroxytryptamine on single cortical neurons. Brain Res 1987, 423:347.
134. Matsuyama S, Nei K, Tanaka C Regulation of glutamate release via NMDA and 5-HT1A receptors in guinea pig dentate gyrus. Brain Res 1996, 728:175.
135. Schaper C, Zhu Y, Kouklei M, et al. Stimulation of 5-HT1A receptors reduces apoptosis after transient forebrain ischemia in the rat. Brain Res 2000, 883:41.
136. Ramirez-Lessepas M, Patrick BK, Snyder BD, Lakatua DJ Failure of central nervous system serotonin blockage to influence outcome in acute cerebral infarction: A double blind randomized trial. Stroke 1986, 17:953.
137. Semkova I, Wolz P, Krieglstein J Neuroprotective effect of 5-HT1A receptor agonist, BAY × 3702, demonstrated in vitro and in vivo. Eur J Pharmacol 1998, 359:251.
138. Bayer Randomized Acute Ischemia Neuroprotectant Study (BRAINS). Abstracts from the 4th World Stroke Congress. Stroke 2000, 31:2768.
139. Teal P, Rombout F, Weber H, et al: Repinotan (BAY × 3702) in acute ischemic stroke: A randomized exposure controlled trial. Abstract presented in the Ongoing Clinical Trials Session, 26th International Stroke Conference, February 13-15, 2001, Fort Lauderdale, FL.
140. ONO-2506 in Acute Ischemic Stroke. In Stroke Center Clinical Trials Directory. Available at Updated 11/14/2002 . http://www.mtsinai.org/pulmonary/books/house/legal.html.
141. Harini RJ, Supra EL, Roberts JP, Lavyne MH Effect of naloxone on cerebral perfusion and cardiac performance during experimental cerebral ischemia. J Neurosurg 1986, 64:780.
142. Namba S, Nishigaki S, Fujiwara N, et al. Opiate-antagonist reversal of neurological deficits: Experimental and clinical studies. Jpn J Psych Neurol 1986, 40:61.
143. Baskin DS, Juroda H, Hosobuchi Y, Lee NM Treatment of stroke with opiate antagonists: Effects of exogenous antagonist and dynorphin 1-13. Neuropeptides 1985, 5:307.
144. Fallis RF, Fisher M, Lobo RA A double blind trial of naloxone in the treatment of acute stroke. Stroke 1984, 15:627.
145. Jabaily J, Davis JN Naloxone administration to patients with acute stroke. Stroke 1984, 15:36.
146. Adams HP, Olinger CP, Barsan WG, et al. A dose-escalation study of large doses of naloxone for treatment of patients with acute cerebral ischemia. Stroke 1986, 17:404.
147. Olinger CP, Adams HP, Brott TG, et al. High-dose intravenous naloxone for the treatment of acute ischemic stroke. Stroke 1990, 21:721.
148. Federico F, Lucivero V, Lamberti P, et al. A double blind randomized pilot trial of naloxone in the treatment of acute ischemic stroke. Ital J Neurol Sci 1991, 12:557.
149. Clark W, Coull B, Karukin M, et al. Randomized trial of Cervene, a κ receptor-selective opioid antagonist, in acute ischemic stroke. J Stroke Cerebrovasc Dis 1996, 6:35.
150. Clark W, Ertag W, Orecchio E, Raps E Cervene in acute ischemic stroke: Results of a double-blind, placebo-controlled, dose-comparison study. J Stroke Cerebrovasc Dis 1999, 8:224.
151. Clark WM, Raps EC, Tong DC, Kelly RE Cervene (nalmefene) in acute ischemic stroke: Final results of a phase III efficacy study. The Cervene Stroke Study Investigators. Stroke 2000, 31:1234.
152. Green AR, Hainsworth AH, Jackson DM GABA potentiation: A logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology 2000, 39:1483.
153. Moody IF, Skolnick P Clomethiazole: Neurochemical actions at the gamma-aminobutyric acid complex. Br J Pharmacol 1989, 164:153.
154. Cross AF, Jones JA, Snares M, et al. Neuroprotective activity of clomethiazole following transient forebrain ischemia in the gerbil. Br J Pharmacol 1991, 104:406.
155. Marshall JWB, Cross AF, Murray TK, Ridley RM Functional benefit from clomethiazole treatment after focal cerebral ischaemia in a non-human primate species [abstract]. Stroke 1998, 29:330.
156. Wester P, Strand T, Wahlgren NG, et al. An open study of clomethiazole in patients with acute cerebral infarction. Cerebrovasc Dis 1998, 8:188.
157. Sydserff SG, Cross AJ, Murray TK, et al. Clomethiazole is neuroprotective in models of global and focal cerebral ischemia when infused at doses producing clinically relevant plasma concentrations. Brain Res 2000, 862:59.
158. Wahlgren NG, Ranasinha KW, Rosolacci T, et al. Clomethiazole Acute Stroke Study (CLASS): Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients. The CLASS Study Group. Stroke 1999, 30:21.
159. Wahlgren NG, Diez-Tejedor E, Teitelbaum J, et al. Results in 95 hemorrhagic stroke patients included in CLASS, a controlled trial of clomethiazole versus placebo in acute stroke patients. The CLASS Study Group. Stroke 2000, 31:82.
160. Lyden P, Shuaib A, Ng K, et al. Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): Final results. The CLASS-I/H/T Investigators. Stroke 2002, 33:122.
161. Lodder J, Raak van EPM, Kessels F: Early GABA-ergic activation study in stroke. Abstract presented at the Ongoing Clinical Trials Session, 26th International Stroke Conference, February 13-15, 2001, Fort Lauderdale, FL.
162. Hall ED, Pazara KE, Braughler JM 21-Aminosteroid lipid peroxidation inhibitor U74006F protects against cerebral ischemia in gerbils. Stroke 1988, 19:997.
163. Zuccarello M, Marsch JT, Schmitt G, et al. Effect of the 21-aminosteroid U-74006 on cerebra vasospasm following subarachnoid hemorrhage. J Neurosurg 1989, 71:98.
164. Hall ED, Andrus PK, Smith SL, et al. Neuroprotective efficacy of microvascularly-localized versus brain-penetrating antioxidants. Acta Neurochir Suppl (Wien) 1996, 66:107.
165. Safety study of tirilazad mesylate in patients with acute ischemia stroke (STIPAS). The STIPAS Investigators. Stroke 1994, 25:418.
166. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). The RANTTAS Investigators. Stroke 1996, 27:1453.
167. Haley EC High-dose tirilazad for acute stroke (RANTTAS II). The RANTTAS II Investigators. Stroke 1998, 29:1256.
168. Tirilazad mesylate in acute ischemic stroke A systematic review. Tirilazad International Steering Committee. Stroke 2000, 32:2257.
169. Van der Worp HB, Kappelle LJ, Algra A, et al. The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke. The TESS and TESS II Investigators. Neurology 2002, 58:133.
170. Beck T, Bielenberg GW Failure of the lipid peroxidation inhibitor U74006F to improve neurological outcome after transient forebrain ischemia in the rat. Brain Res 1990, 532:336.
171. Ichikawa S, Omura K, Katayama T, et al. Inhibition of superoxide anion production in guinea pig polymorphonuclear leukocytes by a seleno-organic compound, ebselen. J Pharmacobio-Dyn 1987, 10:595.
172. Hattori R, Inoue R, Sase K, et al. Preferential inhibition of inducible nitric oxide synthase by ebselen. Eur J Pharmacol 1994, 267:R1.
173. Maiorino M, Roveri A, Coassin M, Ursini F Kinetic mechanism and substrate specificity of glutathione peroxidase activity of ebselen (PZ51). Biochem Pharmacol 1988, 37:2267.
174. Takasago T, Peters EE, Graham DI, et al. Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Br J Pharmacol 1997, 122:1251.
175. Yamaguchi T, Sano K, Takakura K, et al. Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial. The Ebselen Study Group. Stroke 1998, 29:12.
176. Zhao Z, Cheng M, Maples KR, et al. NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res 2001, 909:46.
177. Sydserff SG, Borelli AR, Green AR, Cross AJ Effect of NSY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat: Studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 2002, 135:103.
178. Kuroda S, Tsuchidate R, Smith ML, et al. Neuroprotective effects of a novel nitrone, NCY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1999, 19:778.
179. Marshall JWB, Duffin KJ, Green AR, Ridley RM NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 2001, 32:190.
180. Cross AJ: The effect of increasing doses of NXY-059 on infarct size following permanent middle cerebral artery occlusion in the rat. AstraZeneca Report 805-61 AN 062-01, 2000-06-09.
181. Lees KR, Sharma AK, Barer D, et al. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. The SANXY-0003 Investigators. Stroke 2001, 32:675.
182. Okada Y, Copeland BR, More E, et al. P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke 1994, 25:202.
183. Zhang RL, Chopp M, Zaloga C, et al. The temporal profiles of ICAM-1 protein and mRNA expression after transient MCA occlusion in the rat. Brain Res 1995, 682:182.
184. Soriano SG, Coxon A, Wang YF, et al. Mice deficient in Mac-1 (CD11b/CD18) are less susceptible to cerebral ischemia/reperfusion injury. Stroke 1999, 30:134.
185. Kitagawa K, Matsumoto M, Mabuchi T, et al. Deficiency of intercellular adhesion molecule-1 attenuates microcirculatory disturbance and infarction size in focal cerebral ischemia. J Cereb Blood Flow Metab 1998, 18:1336.
186. Clark WM, Madden KP, Rothlein R, Zivin JA Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. Stroke 1991, 22:877.
187. Zhang RL, Chopp M, Jiang N, et al. Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. Stroke 1995, 26:1438.
188. Zhang RL, Zhang ZG, Chopp M, Zivin JA Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke 1999, 30:624.
189. Fassbender K, Mossner R, Motsch L, et al. Circulating selectin- and immunoglobulin-type adhesion molecules in acute ischemic stroke. Stroke 1995, 26:1361.
190. Bitsch A, Klene W, Murtada L, et al. A longitudinal prospective study of soluble adhesion molecules in acute stroke. Stroke 1998, 29:2129.
191. Frijns CJ, Kappelle LJ, van Ijn J, et al. Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. Stroke 1997, 28:2214.
192. Lindsberg PJ, Carpen O, Paetau A, et al. Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation 1996, 94:939.
193. Schneider D, Berrouschot J, Brandt T, et al. Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1. antibody): An open-label, dose escalation study in patients hospitalized for acute stroke. European Neurol 1998, 40:78.
194. Use of anti-ICAM-1 therapy in ischemic stroke: Results of the Enlimomab Acute Stroke Trial. Enlimomab Acute Stroke Trial Investigators. Neurology 2001, 57:1428.
195. Furuya K, Takeda H, Axhar S, et al. Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: A bedside-to-bench study. Stroke 2001, 32:2665.
196. ICOS halts trial of stroke drug, reports Q1 net loss. April 20th, 2000. Available at . http://www.mtsinai.org/pulmonary/books/house/legal.html.
197. Jiang N, Chopp M, Chahwala S Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat. Brain Res 1998, 788:25.
198. UK-279,276 Stroke Center Clinical Trials Directory. Available at Updated 5/9/2002. http://www.mtsinai.org/pulmonary/books/house/legal.html.
199. Manabat C, Han BH, Wendland M, et al. Reperfusion differentially induces caspases-3 activation in ischemic core and penumbra after stroke in immature brain. Stroke 2003, 34:207.
200. Robertson GS, Crocker SJ, Nicholson DW, Schulz JB Neuroprotection by the inhibition of apoptosis. Brain Pathol 2000, 10:283.
201. Satoh S, Ikegaki I, Suzuki Y, et al. Neuroprotective properties of a protein kinase inhibitor against ischaemia-induced neuronal damage in rats and gerbils. Br J Pharmacol 1996, 118:1592.
202. Wang KKW, Nath R, Rosner A, et al. An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective. Proc Natl Acad Sci U S A 1996, 93:6687.
203. Barone FC, Irving EA, Ray AM, et al. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J Pharmacol Exp Ther 2001, 296:312.
204. Markgraf CG, Velayo NL, Johnson MP, et al. Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. Stroke 1998, 29:152.
205. Yrjanheikki J, Keinanen R, Pellikka M, et al. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 1998, 95:15769.
206. Yrjanheikki J, Tikka T, Keinanen R, et al. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A 1999, 96:13496.
207. Wang C, Yang T, Noor R, Shuaib A Delayed minocycline but not delayed mild hypothermia protects against embolic stroke. BMC Neurol 2002, 2(1).
208. Asai A, Qiu J, Narita Y, et al. High level calcineurin activity predisposes neuronal cells to apoptosis. J Biol Chem 1999, 274:34450.
209. Herr I, Martin-Villalba A, Kurz E, et al. FK506 prevents stroke-induced generation of ceramide and apoptosis signaling. Brain Res 1999, 826:210.
210. Bochelen D, Rudin M, Sauter A Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J Pharmacol Exp Ther 1999, 288:653.
211. Ebisu T, Katsuta K, Fujikawa A, et al. Early and delayed neuroprotective effects of FK506 on experimental focal ischemia quantitatively assessed by diffusion-weighted MRI. Magn Reson Imaging 2001, 19:153.
212. McCarter JF, McGregor AL, Jones PA, Sharkey J FK506 protects brain tissue in animal models of stroke. Transplant Proc 2001, 33:2390.
213. Arii T, Kamiya T, Arii K, et al. Neuroprotective effect of immunosuppressant FK506 in transient focal ischemia in rat: Therapeutic time window for FK506 in transient focal ischemia. Neurol Res 2001, 23:755.
214. Takamatsu H, Tsukada H, Noda A, et al. FK506 attenuates early ischemic neuronal death in a monkey model of stroke. J Nucl Med 2001, 42:1833.
215. Limbourg FP, Huang Z, Plumier JC, et al. Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J Clin Invest 2002, 110:1729.
216. Mulley G, Wilcox RG, Mitchell JR Dexamethasone in acute stroke. BMJ 1978, 2:994.
217. Norris JW, Hachinski VC High dose steroid treatment in cerebral infarction. BMJ 1986, 292:21.
218. Qizilbash N, Lewington SL, Lopez-Arrieta JM: Corticosteroids for acute ischaemic stroke. Cochrane Database Syst Rev CD000064, 2000.
219. Vayssiere BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit anti-inflammatory activity in vivo. Mol Endocrinol 1997, 11:1245.
220. Amin-Hanjani S, Stagliano NE, Yamada M, et al. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 2001, 32:980.
221. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ Stroke, statins, and cholesterol: A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997, 28:946.
222. Belayev L, Liu Y, Zhao W, et al. Human albumin therapy of acute ischemic stroke: Marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001, 32:553.
223. Zoellner H, Hofler M, Beckmann R, et al. Serum albumin is a specific inhibitor of apoptosis in human endothelial cells. J Cell Sci 1996, 109:2571.
224. Rodriguez de Turco IB, Belayev L, Liu Y, et al. Systemic fatty acid responses to transient focal cerebral ischemia: Influence of neuroprotectant therapy with human albumin. J Neurochem 2002, 83:515.
225. Lenzi GL, Grigoletto F, Gent M, et al. Early treatment of stroke with monosialoganglioside GM-1: Efficacy and safety results of the early stroke trial. The Early Stroke Trial Group. Stroke 1994, 25:1552.
226. Schwab M, Antonow-Schorke I, Zwiener U, Bauer R Brain-derived peptides reduce the size of cerebral infarction and loss of MAP2 immunoreactivity after focal ischemia in rats. J Neural Transm Suppl 1998, 53:299.
227. Ladurner F Neuroprotection in acute ischaemic stroke [abstract]. Stroke 2001, 32:323.
228. Rao AM, Hatcher JF, Dempsey RJ CDP-choline: Neuroprotection in transient forebrain ischemia of gerbils. J Neurosci Res 1999, 58:697.
229. Adibhatla RM, Hatcher JF, Dempsey RJ Citicoline: Neuroprotective mechanisms in cerebral ischemia. J Neurochem 2002, 80:12.
230. Krupinski J, Ferrer I, Barrachina M, et al. CDP-choline reduces procaspase and cleaved caspae-3 expression, nuclear DNA fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. Neuropharmacology 2002, 42:846.
231. Galleti P, DeRosa M, Cotticelli MG, et al. Biochemical rationale for the use of CDP-choline in traumatic brain injury: Pharmacokinetics of the orally administered drug. J Neurol Sci 1991, 103:S19.
232. Clark W, Warach S A randomized dose-response trial of citicoline in acute ischemic stroke patients. The Citicoline Study Group. Neurology 1997, 49:671.
233. Clark WM, Williams BJ, Selzer KA, et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. The Citicoline Stroke Study Group. Stroke 1999, 30:2592.
234. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. The Citicoline Stroke Study Group. Neurology 2001, 57:1595.
235. Corso A, Arena M, Ventimiglia A, et al. CDP-choline for cerebrovascular disorders: Clinical evaluation and evaluation of electrophysiological symptomology. Clin Ter 1982, 102:370.
236. Tazaki Y, Sakai F, Otomo E, et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke 1988, 19:211-216.
237. Saver J, Wilterdink J Choline precursors in acute and subacute stroke: A meta-analysis. Stroke 2002, 32:1598.
238. Andersen M, Overgaard K, Meden P, Boysen G Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke 1999, 30:1464.
239. Toung TJK, Traystman RJ, Hurn PD Estrogen-mediated neuroprotection after experimental stroke in male rates. Stroke 1998, 29:1666.
240. Simpkins JW, Rajakumar G, Zhang YQ, et al. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J Neurosurg 1997, 87:724.
241. Dubal DB, Shughrue PJ, Wilson ME, et al. Estradiol modulates bcl-2 in cerebral ischemia: A potential role for estrogen receptors. J Neurosci 1999, 19:6385.
242. Green PS, Simpkins JW Neuroprotective effects of estrogens: Potential mechanisms of action. Int J Dev Neurosci 2000, 8:347.
243. Paganini-Hill A, Ross RK, Henderson BE Postmenopausal oestrogen treatment and stroke: A prospective study. BMJ 1988, 297:519.
244. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999, 91:1829.
245. Pardridge WM Drug delivery to the brain. J Cereb Blood Flow Metab 1997, 17:713.
246. Siren AL, Ehrenreich H Erythropoietin-a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci 2001, 251:179.
247. Sakanaka M, Wen TC, Matsuda S, et al. In vitro evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 1998, 95:4635.
248. Morishita E, Masuda S, Nagao M, et al. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997, 76:105.
249. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 2000, 97:10526.
250. Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 2000, 98:4044.
251. Ay I, Sugimori H, Finklestein SP Intravenous basic fibroblast growth factor (bFGF) decreases DNA fragmentation and prevents downregulation of Bcl-2 expression in the ischemic brain following middle cerebral artery occlusion in rats. Mol Brain Res 2001, 87:71.
252. Kawamata T, Kietrich WD, Schallert T, et al. Intracisternal basic fibroblast growth factor enhances functional recovery and upregulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction. Proc Natl Acad Sci U S A 1997, 94:8179.
253. Li Q, Stephenson D Postischemic administration of basic fibroblast growth factor improves sensorimotor function and reduces infarct size following permanent focal cerebral ischemia in the rat. Exp Neurol 2002, 177:531.
254. Schabitz WR, Li F, Irie K, et al. Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. Stroke 1999, 30:427.
255. Ma J, Aui J, Hirt L, et al. Synergistic protective effect of caspases inhibitors and bFGF against brain injury induced by transient focal ischaemia. Br J Pharmacol 2001, 133:345.
256. Bogousslavsky J, Victor SJ, Salinas EO, et al. Fiblast (trafermin) in acute stroke: Results of the European-Australian phase II/III safety and efficacy trial. The European-Australian Fiblast in Acute Stroke Group. Cerebrovasc Dis 2002, 14:239.
257. Song BW, Vinters HV, Wu D, Pardridge WM Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J Pharmacol Exp Ther 2002, 301:605.
258. Krupinski J, Issa R, Bujny T, et al. A putative role for platelet-derived growth factor in angiogenesis and neuroprotection after ischemic stroke in humans. Stroke 1997, 28:564.
259. Semkova I, Krieglstein J Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors. Brain Res Rev 1999, 30:176.
260. Wang Y, Chang CF, Morales M, et al. Protective effects of glial cell line-derived neurotrophic factor in ischemic brain injury. Ann N Y Acad Sci 2002, 962:423.
261. Kilic E, Dietz GPH, Hermann DM, Bahr M Intravenous TAT-Bcl-XL is protective after middle cerebral artery occlusion in mice. Ann Neurol 2002, 52:617.
262. Busto R, Dietrich WD, Globus MYT, et al. Small differences in intraischemic brain temperature critically determine the extent of ischemic neuronal injury. J Cereb Blood Flow Metab 1987, 7:729.
263. Buchan A, Pulsinell WA Hypothermia but not N-methyl-D-aspartate antagonist MK-801 attenuates neuronal damage in gerbils subjected to transient global ischemia. J Neurosci 1990, 10:311.
264. Minamisawa H, Nordstrom CH, Smith ML, Siesjo BK The influence of mild body and brain hypothermia on ischemic brain damage. J Cereb Blood Flow Metab 1990, 10:365.
265. Coimbra C, Wielock T Hypothermia ameliorates neuronal survival when induced 2 hours after ischemia in the rat. Acta Physiol Scand 1992, 146:543.
266. Meden P, Overguard K, Pedersen H, Boysen G The influence of body temperature on infarct volume and thrombolytic therapy in a rat embolic stroke model. Brain Res 1994, 647:131.
267. Corbett D, Nurse S, Colbourne F Hypothermic neuroprotection: A global ischemia study using 18- to 20-month-old gerbils. Stroke 1997, 28:2238.
268. Barone FC, Feuerstein GZ, White RF Brain cooling during transient focal ischemia provides complete neuroprotection. Neurosci Biobehav Rev 1997, 21:31.
269. Maier CM, Ahern KB, Cheng MD, et al. Optimal depth and duration of mild hypothermia in a focal model of transient cerebral ischemia: Effects of neurologic outcome, infarct size, apoptosis, and inflammation. Stroke 1998, 29:2191.
270. Corbett D, Hamilton M, Colbourne F Persistent neuroprotection with prolonged postischemic hypothermia in adult rats subjected to transient middle cerebral artery occlusion. Exp Neurol 2000, 163:200.
271. Kawai N, Okauchi M, Morisaki K, Nagao S Effects of delayed intraischemic and postischemic hypothermia on a focal model of transient cerebral ischemia in rats. Stroke 2000, 31:1982.
272. Nakashima K, Todd MM Effects of hypothermia on the rate of excitatory amino acid release after ischemic depolarization. Stroke 1996, 27:913.
273. Koizumi H, Fujisawa H, Ito H, et al. Effects of mild hypothermia on cerebral blood flow-independent changes in cortical extracellular levels of amino acids following contusion trauma in the rat. Brain Res 1997, 747:304.
274. Sick TJ, Xu G, Perez-Pinzon AM Mild hypothermia improves recovery of cortical extracellular potassium ion activity and excitability after middle cerebral artery occlusion in the rat. Stroke 1999, 30:2416.
275. Babu PP, Yoshida Y, Su M, et al. Immunohistochemical expression of Bcl-2, Bax and cytochrome c following focal cerebral ischemia and effect of hypothermia in rat. Neurosci Lett 2000, 291:196.
276. Ishikawa M, Sekizuka E, Sato S, et al. Effects of moderate hypothermia on leukocyte-endothelium interaction in the rat pial microvasculature after transient middle cerebral artery occlusion. Stroke 1999, 30:1679.
277. Inamasu J, Suga S, Sato S, et al. Post-ischemic hypothermia delayed neutrophil accumulation and microglial activation following transient focal cerebral ischemia in rats. J Neuroimmunol 2000, 109:66.
278. Zeiner A, Holzer M, Sterz F, et al. Mild resuscitative hypothermia to improve neurological outcome after cardiac arrest. The Hypothermia After Cardiac Arrest (HACA) Study Group. Stroke 2000, 31:86.
279. Felberg RA, Krieger DW, Chuang R, et al. Hypothermia after cardiac arrest: Feasibility and safety of an external cooling protocol. Circulation 2001, 104:1799.
280. Azzimondi G, Bassein L, Nonino F, et al. Fever in acute stroke worsens prognosis. Stroke 1995, 26:2040.
281. Jorgensen HS, Reith J, Pedersen PM, et al. Body temperature and outcome in stroke patients [letter]. Lancet 1996, 348:193.
282. Reith J, Jorgensen HS, Pedersen PM, et al. Body temperature in acute stroke: Relation to stroke severity, infarct size, mortality, and outcome. Lancet 1996, 347:422.
283. Wang Y, Lim LL, Levi C, et al. Influence of admission body temperature on stroke mortality. Stroke 2000, 31:404.
284. Schwab S, Schwarz S, Spranger M, et al. Moderate hypothermia in the treatment of patients with severe middle cerebral artery infarction. Stroke 1998, 29:2461.
285. Kammersgaard LP, Rasmussen BH, Jorgensen HS, et al. Feasibility and safety of inducing modest hypothermia in awake patients with acute stroke through surface cooling: A case-control study. Stroke 2000, 31:2251.
286. Schwab S, Georgiadis D, Berrouschot J, et al. Feasibility and safety of moderate hypothermia after massive hemispheric infarction. Stroke 2001, 32:2033.
287. Steiner T, Friede T, Aschoff A, et al. Effect and feasibility of controlled rewarming after moderate hypothermia in stroke patients with malignant infarction of the middle cerebral artery. Stroke 2001, 32:2833.
288. Kreiger DW, DeGeorgia MA, Abou-Chebl A, et al. Cooling for Acute Ischemic Brain Damage (COOL AID): An open pilot study of induced hypothermia in acute ischemic stroke. Stroke 2001, 32:1847.
289. Georgiadis D, Schwarz S, Kollmar R, Schwab S Endovascular cooling for moderate hypothermia in patients with acute stroke: First results of a novel approach. Stroke 2001, 32:2550.
290. Strong R, Grotta JC, Aronowski J Combination of low dose ethanol and caffeine protects brain from damage produced by focal ischemia in rats. Neuropharmacology 2000, 39:515.
291. Aronowski J, Strong R, Shirzadi A, Grotta J Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke 2003, 34:1246.
292. Piriyawat P, Labiche LA, Burgin WS, et al. Pilot dose-escalation study of caffeine plus ethanol (caffeinol) in acute ischemic stroke. Stroke 2003, 34:1242.
293. Bowes M, Burhop K, Zivin J Diaspirin cross-linked hemoglobin improves neurological outcome following reversible but not irreversible CNS ischemia in rabbits. Stroke 1994, 25:2253.
294. Cole D, Schell R, Przybelski R, et al. Focal cerebral ischemia in rats: Effect of hemodilution with cross-linked hemoglobin on CBF. J Cereb Blood Flow Metab 1992, 12:971.
295. Cole D, Schell R, Drummond J, Reynolds L Focal cerebral ischemia in rats: Effect of hypervolemic hemodilution with diaspirin crossed-linked hemoglobin versus albumin on brain injury and edema. Anesthesiology 1993, 78:335.
296. Grotta J, Aronowski J DCLHb for focal ischemia and reperfusion. Cerebrovasc Dis 1996, 6:189.
297. Saxena R, Wijnhoud AD, Carton H, et al. Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Stroke 1999, 30:993.
298. Singhal AB, Dijkhuizen RM, Rosen B, Lo EH Normobaric hyperoxia reduces MRI diffusion abnormalities and infarct size in experimental stroke. Neurology 2002, 58:945.
299. Atochin DN, Fisher D, Demchenko IT, Thom SR Neutrophil sequestration and the effect of hyperbaric oxygen in a rat model of temporary middle cerebral artery occlusion. Undersea Hyperb Med 2000, 27:185.
300. Badr AE, Yin W, Mychaskiw G, Zhang JH Effect of hyperbaric oxygen on striatal metabolites: A microdialysis study in awake freely moving rats after MCA occlusion. Brain Res 2001, 916:85.
301. Burt JT, Kapp JP, Smith RR Hyperbaric oxygen and cerebral infarction in the gerbil. Surg Neurol 1987, 28:265.
302. Weinstein PR, Anderson GG, Telles DA Results of hyperbaric oxygen therapy during temporary middle cerebral artery occlusion in unanesthetized cats. Neurosurg 1987, 20:518.
303. Veltkamp R, Warner DS, Domoki F, et al. Hyperbaric oxygen decreases infarct size and behavioral deficit after transient focal cerebral ischemia in rats. Brain Res 2000, 853:68.
304. Chang CF, Niu KC, Hoffer BJ, et al. Hyperbaric oxygen therapy for treatment of postischemic stroke in adult rats. Exp Neurol 2000, 166:298.
305. Sunami K, Takeda Y, Hashimoto M, Hirakawa M Hyperbaric oxygen reduces infarct volume in rats by increasing oxygen supply to the ischemic periphery. Crit Care Med 2000, 28:2831.
306. Jacobson I, Lawson DD The effect of hyperbaric oxygen on experimental cerebral infarction in the dog. J Neurosurg 1963, 20:849.
307. Roos JA, Jackson-Friedman C, Lyden P Effects of hyperbaric oxygen on neurologic outcome for cerebral ischemia in rats. Acad Emerg Med 1998, 5:18.
308. Hjelde A, Hjelstuen M, Haraldseth O, et al. Hyperbaric oxygen and neutrophil accumulation/tissue damage during permanent focal cerebral ischaemia in rats. Eur J Appl Physiol 2002, 86:401.
309. Anderson DC, Bottini AG, Jagiella WM, et al. A pilot study of hyperbaric oxygen in the treatment of human stroke. Stroke 1991, 22:1137.
310. Nighoghossian N, Trouillas P, Adeleine P, Salord F Hyperbaric oxygen in the treatment of acute ischemic stroke: A double-blind pilot study. Stroke 1995, 26:1369.